Two Sigma Advisers LP Has $2.70 Million Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Two Sigma Advisers LP decreased its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 22.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 889,700 shares of the company's stock after selling 259,700 shares during the period. Two Sigma Advisers LP owned about 1.25% of Zentalis Pharmaceuticals worth $2,696,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Almitas Capital LLC increased its stake in shares of Zentalis Pharmaceuticals by 69.3% during the fourth quarter. Almitas Capital LLC now owns 1,626,896 shares of the company's stock valued at $4,929,000 after buying an additional 665,968 shares during the period. Primecap Management Co. CA increased its stake in shares of Zentalis Pharmaceuticals by 1.5% during the fourth quarter. Primecap Management Co. CA now owns 1,520,630 shares of the company's stock valued at $4,608,000 after buying an additional 22,600 shares during the period. Geode Capital Management LLC increased its stake in shares of Zentalis Pharmaceuticals by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 1,312,964 shares of the company's stock valued at $3,979,000 after buying an additional 20,864 shares during the period. D. E. Shaw & Co. Inc. increased its stake in shares of Zentalis Pharmaceuticals by 9.8% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,239,459 shares of the company's stock valued at $3,756,000 after buying an additional 110,882 shares during the period. Finally, Integral Health Asset Management LLC purchased a new position in shares of Zentalis Pharmaceuticals during the fourth quarter valued at $3,182,000.

Insider Transactions at Zentalis Pharmaceuticals

In related news, Director Scott Dunseth Myers bought 21,000 shares of the stock in a transaction on Wednesday, April 30th. The shares were bought at an average cost of $1.40 per share, for a total transaction of $29,400.00. Following the purchase, the director now owns 281,192 shares of the company's stock, valued at $393,668.80. This trade represents a 8.07% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 1.90% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Wedbush restated a "neutral" rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th. Finally, Wells Fargo & Company dropped their price objective on Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 30th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $8.24.

Zentalis Pharmaceuticals Stock Performance

Shares of Zentalis Pharmaceuticals stock remained flat at $1.25 during trading hours on Thursday. The stock had a trading volume of 661,756 shares, compared to its average volume of 1,556,989. Zentalis Pharmaceuticals, Inc. has a twelve month low of $1.01 and a twelve month high of $13.00. The company's fifty day simple moving average is $1.33 and its two-hundred day simple moving average is $2.19. The company has a market cap of $89.94 million, a PE ratio of -0.50 and a beta of 1.81.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.67). Equities analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.